Inhibitors targeting both EZH1 and EZH2 (EZH1/2 dual inhibitors) and EED (EED inhibitor) have also been developed [102,103,104], and these inhibitors show better tumor-eradicating effects than EZH2-specific inhibitors in the treatment of AML, multiple myeloma, and EZH2 inhibitor-resistant DLBCL cells [105,106,107,108,109,110]. Here, EZH2 is linked to plasma cell myeloma.